Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer...
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
About this item
Full title
Author / Creator
Kerr, Rachel S, Dr , Love, Sharon, BSc , Segelov, Eva, FRACP , Johnstone, Elaine, PhD , Falcon, Beverly, PhD , Hewett, Peter, FRACS , Weaver, Andrew, MD , Church, David, MRCP , Scudder, Claire, MSc , Pearson, Sarah, BSc , Julier, Patrick, MSc , Pezzella, Francesco, Prof , Tomlinson, Ian, Prof , Domingo, Enric, PhD and Kerr, David J, FRCP
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Antiangiogenic agents have established efficacy in the treatment of metastatic colorectal cancer. We investigated whether bevacizumab could improve disease-free survival in the adjuvant setting after resection of the primary tumour. Methods For the open-label, randomised, controlled QUASAR 2 trial, which was done at 170 hospitals...
Alternative Titles
Full title
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Authors, Artists and Contributors
Author / Creator
Love, Sharon, BSc
Segelov, Eva, FRACP
Johnstone, Elaine, PhD
Falcon, Beverly, PhD
Hewett, Peter, FRACS
Weaver, Andrew, MD
Church, David, MRCP
Scudder, Claire, MSc
Pearson, Sarah, BSc
Julier, Patrick, MSc
Pezzella, Francesco, Prof
Tomlinson, Ian, Prof
Domingo, Enric, PhD
Kerr, David J, FRCP
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1837590438
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1837590438
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(16)30172-3
